Escitalopram

Generic name: Pronounced as (es sye tal' oh pram)
Brand names
  • Lexapro®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 01/15/2022

A small number of children, teenagers, and young adults (up to 24 years of age) who took antidepressants ('mood elevators') such as escitalopram during clinical studies became suicidal (thinking about harming or killing oneself or planning or trying to do so). Children, teenagers, and young adults who take antidepressants to treat depression or other mental illnesses may be more likely to become suicidal than children, teenagers, and young adults who do not take antidepressants to treat these conditions. However, experts are not sure about how great this risk is and how much it should be considered in deciding whether a child or teenager should take an antidepressant. Children younger than 12 years of age should not normally take escitalopram, but in some cases, a doctor may decide that escitalopram is the best medication to treat a child's condition.

You should know that your mental health may change in unexpected ways when you take escitalopram or other antidepressants even if you are an adult over 24 years of age. You may become suicidal, especially at the beginning of your treatment and any time that your dose is increased or decreased. You, your family, or your caregiver should call your doctor right away if you experience any of the following symptoms: new or worsening depression; thinking about harming or killing yourself, or planning or trying to do so; extreme worry; agitation; panic attacks; difficulty falling asleep or staying asleep; aggressive behavior; irritability; acting without thinking; severe restlessness; and frenzied abnormal excitement. Be sure that your family or caregiver knows which symptoms may be serious so they can call the doctor if you are unable to seek treatment on your own.

Your healthcare provider will want to see you often while you are taking escitalopram, especially at the beginning of your treatment. Be sure to keep all appointments for office visits with your doctor.

The doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with escitalopram. Read the information carefully and ask your doctor or pharmacist if you have any questions. You also can obtain the Medication Guide from the FDA website: http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm.

No matter your age, before you take an antidepressant, you, your parent, or your caregiver should talk to your doctor about the risks and benefits of treating your condition with an antidepressant or with other treatments. You should also talk about the risks and benefits of not treating your condition. You should know that having depression or another mental illness greatly increases the risk that you will become suicidal. Tell your doctor if you or anyone in your family has or has ever had bipolar disorder (mood that changes from depressed to abnormally excited) or mania (frenzied, abnormally excited mood) or has thought about or attempted suicide. Talk to your doctor about your condition, symptoms, and personal and family medical history. You and your doctor will decide what type of treatment is right for you.

Escitalopram is used to treat depression in adults and children and teenagers 12 years of ago or older. Escitalopram is also used to treat generalized anxiety disorder (GAD; excessive worry and tension that disrupts daily life and lasts for 6 months or longer) in adults. Escitalopram is in a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs). It works by increasing the amount of serotonin, a natural substance in the brain that helps maintain mental balance.

Escitalopram comes as a tablet and a solution (liquid) to take by mouth. It is usually taken once a day with or without food. To help you remember to take escitalopram, take it at around the same time every day, in the morning or in the evening. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take escitalopram exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Your doctor may start you on a low dose of escitalopram and increase your dose after 1 week.

It may take 1 to 4 weeks or longer before you feel the full benefit of escitalopram. Continue to take escitalopram even if you feel well. Do not stop taking escitalopram without talking to your doctor. Your doctor will probably decrease your dose gradually. If you suddenly stop taking escitalopram, you may experience withdrawal symptoms such as mood changes, irritability, agitation, nausea, dizziness, burning, numbness, or tingling in the hands or feet, anxiety, confusion, headache, sweating, shaking, frenzied or abnormally excited mood, tiredness, and difficulty falling asleep or staying asleep. Tell your doctor if you experience any of these symptoms while you are decreasing your dose of escitalopram or soon after you stop taking escitalopram.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before taking escitalopram,

  • tell your doctor or pharmacist if you are allergic to escitalopram, citalopram (Celexa), any other medications, or any of the ingredients in the tablets or solution. Ask your pharmacist or check the Medication Guide for a list of the ingredients.

  • tell your doctor if you are taking pimozide (Orap) or a monoamine oxidase (MAO) inhibitor such as isocarboxazid (Marplan), linezolid (Zyvox), methylene blue, phenelzine (Nardil), selegiline (Emsam, Zelapar), and tranylcypromine (Parnate), or if you have stopped taking an MAO inhibitor within the past 14 days. Your doctor will probably tell you not to take escitalopram. If you stop taking escitalopram, you should wait at least 14 days before you start to take an MAO inhibitor.

  • you should know that escitalopram is very similar to another SSRI, citalopram (Celexa). You should not take these two medications together.

  • tell your doctor or pharmacist what prescription and nonprescription medications and vitamins you are taking or plan to take. Be sure to mention any of the following: anticoagulants ('blood thinners') such as warfarin (Coumadin, Jantoven); amphetamines such as amphetamine (in Adderall, in Mydayis), dextroamphetamine (Dexedrine, in Adderall), and methamphetamine (Desoxyn); aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil, Motrin) and naproxen (Aleve, Naprosyn); buspirone; carbamazepine (Carbatrol, Equetro, Tegretol, others); cimetidine (Tagamet); diuretics ('water pills'); fentanyl (Actiq, Duragesic, Fentora, Subsys); ketoconazole (Sporanox); lithium (Lithobid); medications for anxiety, mental illness, or seizures; medications for migraine headaches such as almotriptan, eletriptan (Relpax), frovatriptan (Frova), naratriptan (Amerge), rizatriptan (Maxalt), sumatriptan (Imitrex, Tosymra, in Treximet), and zolmitriptan (Zomig); metoprolol (Lopressor, Toprol XL); other SSRIs such as fluoxetine (Prozac, in Symbyax), fluvoxamine (Luvox), paroxetine (Paxil), and sertraline (Zoloft); serotonin–norepinephrine reuptake inhibitors (SNRI) such as duloxetine (Cymbalta); sedatives; sleeping pills; tramadol (Conzip, Qdolo, Ultram, in Ultracet); tranquilizers; and tricyclic antidepressants such as amitriptyline, amoxapine, clomipramine (Anafranil), desipramine (Norpramin), doxepin (Silenor), imipramine (Tofranil), nortriptyline (Pamelor), protriptyline, and trimipramine. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • tell your doctor what nutritional supplements and herbal products you are taking, especially products containing St. John's wort or tryptophan.

  • tell your doctor if you have a low level of sodium in your blood, if you drink or have ever drunk large amounts of alcohol, or use or have ever used street drugs or have ever overused prescription medications. Also tell your doctor if you have recently had a heart attack and if you have or have ever had high blood pressure; a stroke; bleeding problems; seizures; or liver, kidney, or heart disease.

  • tell your doctor if you are pregnant, especially if you are in the last few months of your pregnancy, or if you plan to become pregnant or are breast-feeding. If you become pregnant while taking escitalopram, call your doctor. Escitalopram may cause problems in newborns following delivery if it is taken during the last months of pregnancy.

  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking escitalopram.

  • you should know that escitalopram may make you drowsy and may affect your judgment, thinking, and movements. Do not drive a car or operate machinery until you know how this medication affects you.

  • remember that alcohol can add to the drowsiness caused by this medication.

  • you should know that escitalopram may cause angle-closure glaucoma (a condition where the fluid is suddenly blocked and unable to flow out of the eye causing a quick, severe increase in eye pressure which may lead to a loss of vision). Talk to your doctor about having an eye examination before you start taking this medication. If you have nausea, eye pain, changes in vision, such as seeing colored rings around lights, and swelling or redness in or around the eye, call your doctor or get emergency medical treatment right away.

Unless your doctor tells you otherwise, continue your normal diet.

Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

  • Escitalopram may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • nausea

    • diarrhea

    • constipation

    • sexual problems in males; decreased sex drive, inability to get or keep an erection, or delayed or absent ejaculation

    • sexual problems in females; decreased sex drive, or delayed orgasm or unable to have an orgasm

    • drowsiness

    • yawning

    • shaking

    • difficulty falling asleep or staying asleep

    • increased sweating

    • dizziness

    • heartburn

    • stomach pain

    • excessive tiredness

    • dry mouth

    • decreased appetite

    • weight loss

    • flu-like symptoms

    • runny nose

    • sneezing

  • Some side effects can be serious. If you experience either of the following symptoms or those listed in the IMPORTANT WARNING or SPECIAL PRECAUTIONS sections, call your doctor immediately:

    • unusual excitement

    • seeing things or hearing voices that do not exist (hallucinating)

    • rash

    • hives or blisters

    • itching

    • fever

    • joint pain

    • difficulty breathing or swallowing

    • swelling of the face, throat, tongue, lips, or eyes

    • fever, sweating, confusion, fast or irregular heartbeat, severe muscle stiffness or twitching, agitation, hallucinations, loss of coordination, nausea, vomiting, or diarrhea

    • abnormal bleeding or bruising

    • nose bleeding

    • headache

    • unsteadiness

    • problems with thinking, concentration, or memory

    • seizures

    • difficult or painful urination

  • Escitalopram may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include:

  • dizziness

  • nausea

  • vomiting

  • drowsiness

  • fast or pounding heartbeat

  • seizures

  • coma (loss of consciousness for a period of time)

Keep all appointments with your doctor.

Before having any laboratory test (especially those that involve methylene blue), tell your doctor and the laboratory personnel that you are taking escitalopram.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Moxifloxacin Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Escitalopram.
Repaglinide Repaglinide The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Escitalopram.
Insulin Glargine (rDNA origin) Injection Insulin Glargine (rDNA origin) Injection The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Escitalopram.
Delavirdine Delavirdine The serum concentration of Escitalopram can be increased when it is combined with Delavirdine.
Nevirapine Nevirapine The serum concentration of Escitalopram can be increased when it is combined with Nevirapine.
Dolasetron Dolasetron The risk or severity of serotonin syndrome can be increased when Dolasetron is combined with Escitalopram.
Anagrelide Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Escitalopram.
Bisacodyl Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Escitalopram.
Cilostazol Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Escitalopram.
Clopidogrel Clopidogrel The risk or severity of bleeding can be increased when Escitalopram is combined with Clopidogrel.
Diphenoxylate Diphenoxylate The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Escitalopram.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Escitalopram.
Fenofibrate Fenofibrate The metabolism of Escitalopram can be decreased when combined with Fenofibrate.
Guanfacine Guanfacine The risk or severity of adverse effects can be increased when Guanfacine is combined with Escitalopram.
Magnesium Hydroxide Magnesium Hydroxide The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Escitalopram.
Magnesium Oxide Magnesium Oxide The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Escitalopram.
Miglitol Miglitol The risk or severity of hypoglycemia can be increased when Miglitol is combined with Escitalopram.
Naratriptan Naratriptan The risk or severity of serotonin syndrome can be increased when Naratriptan is combined with Escitalopram.
Olsalazine Olsalazine The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Olsalazine.
Paregoric Paregoric The risk or severity of serotonin syndrome can be increased when Morphine is combined with Escitalopram.
Penbutolol Penbutolol The serum concentration of Escitalopram can be increased when it is combined with Acebutolol.
Pentazocine Pentazocine The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Escitalopram.
Polyethylene glycol-electrolyte solution (PEG-ES) Polyethylene glycol-electrolyte solution (PEG-ES) The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Escitalopram.
Psyllium Psyllium The therapeutic efficacy of Plantago seed can be decreased when used in combination with Escitalopram.
Ranitidine Ranitidine The metabolism of Escitalopram can be decreased when combined with Ranitidine.
Reserpine Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Escitalopram.
Rizatriptan Rizatriptan The risk or severity of serotonin syndrome can be increased when Rizatriptan is combined with Escitalopram.
Sumatriptan Sumatriptan The risk or severity of adverse effects can be increased when Sumatriptan is combined with Escitalopram.
Tacrolimus Tacrolimus The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Escitalopram.
Tizanidine Tizanidine The risk or severity of adverse effects can be increased when Tizanidine is combined with Escitalopram.
Zolmitriptan Zolmitriptan The risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with Escitalopram.
Famotidine Injection Famotidine Injection The risk or severity of QTc prolongation can be increased when Famotidine is combined with Escitalopram.
Fluconazole Injection Fluconazole Injection The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Escitalopram.
Foscarnet Injection Foscarnet Injection The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Escitalopram.
Hydromorphone Injection Hydromorphone Injection The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Escitalopram.
Levofloxacin Injection Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Escitalopram.
Meperidine Injection Meperidine Injection The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Meperidine.
Metoclopramide Injection Metoclopramide Injection The risk or severity of sedation can be increased when Metoclopramide is combined with Escitalopram.
Metronidazole Injection Metronidazole Injection The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Escitalopram.
Morphine Injection Morphine Injection The risk or severity of serotonin syndrome can be increased when Morphine is combined with Escitalopram.
Altretamine Altretamine The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Escitalopram.
Cyclosporine Cyclosporine The metabolism of Cyclosporine can be decreased when combined with Escitalopram.
Ondansetron Ondansetron The risk or severity of serotonin syndrome can be increased when Ondansetron is combined with Escitalopram.
Enoxaparin Injection Enoxaparin Injection The risk or severity of bleeding can be increased when Escitalopram is combined with Enoxaparin.
Granisetron Granisetron The risk or severity of serotonin syndrome can be increased when Granisetron is combined with Escitalopram.
Olanzapine Olanzapine The risk or severity of serotonin syndrome can be increased when Olanzapine is combined with Escitalopram.
Alosetron Alosetron The risk or severity of adverse effects can be increased when Alosetron is combined with Escitalopram.
Dofetilide Dofetilide The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Escitalopram.
Entacapone Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Escitalopram.
Hydroxychloroquine Hydroxychloroquine The serum concentration of Escitalopram can be increased when it is combined with Hydroxychloroquine.
Meloxicam Meloxicam The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Meloxicam.
Oxcarbazepine Oxcarbazepine The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Escitalopram.
Pantoprazole Pantoprazole The metabolism of Escitalopram can be decreased when combined with Pantoprazole.
Telmisartan Telmisartan The metabolism of Escitalopram can be decreased when combined with Telmisartan.
Zaleplon Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Escitalopram.
Anakinra Anakinra The metabolism of Escitalopram can be increased when combined with Anakinra.
Desloratadine Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Escitalopram.
Linezolid Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Escitalopram.
Pentosan Polysulfate Pentosan Polysulfate The risk or severity of bleeding can be increased when Escitalopram is combined with Pentosan polysulfate.
Rivastigmine Rivastigmine The therapeutic efficacy of Escitalopram can be decreased when used in combination with Rivastigmine.
Trimipramine Trimipramine The risk or severity of serotonin syndrome can be increased when Trimipramine is combined with Escitalopram.
Etanercept Injection Etanercept Injection The metabolism of Escitalopram can be increased when combined with Etanercept.
Glycopyrrolate Glycopyrrolate The risk or severity of adverse effects can be increased when Escitalopram is combined with Glycopyrronium.
Modafinil Modafinil The metabolism of Escitalopram can be decreased when combined with Modafinil.
Choline Magnesium Trisalicylate Choline Magnesium Trisalicylate The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Choline magnesium trisalicylate.
Zonisamide Zonisamide The risk or severity of adverse effects can be increased when Zonisamide is combined with Escitalopram.
Adalimumab Injection Adalimumab Injection The metabolism of Escitalopram can be increased when combined with Adalimumab.
Aripiprazole Aripiprazole The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Aripiprazole.
Atomoxetine Atomoxetine The metabolism of Atomoxetine can be decreased when combined with Escitalopram.
Dexmethylphenidate Dexmethylphenidate The risk or severity of serotonin syndrome can be increased when Dexmethylphenidate is combined with Escitalopram.
Teriparatide Injection Teriparatide Injection The therapeutic efficacy of Teriparatide can be decreased when used in combination with Escitalopram.
Atazanavir Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Escitalopram.
Almotriptan Almotriptan The risk or severity of serotonin syndrome can be increased when Almotriptan is combined with Escitalopram.
Eletriptan Eletriptan The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Eletriptan.
Mefloquine Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Escitalopram.
Polyethylene Glycol 3350 Polyethylene Glycol 3350 The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Escitalopram.
Vardenafil Vardenafil The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Escitalopram.
Alfuzosin Alfuzosin The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Alfuzosin.
Aprepitant Aprepitant The metabolism of Escitalopram can be decreased when combined with Aprepitant.
Memantine Memantine The metabolism of Escitalopram can be decreased when combined with Memantine.
Tegaserod Tegaserod The risk or severity of serotonin syndrome can be increased when Tegaserod is combined with Escitalopram.
Frovatriptan Frovatriptan The risk or severity of serotonin syndrome can be increased when Frovatriptan is combined with Escitalopram.
Gemifloxacin Gemifloxacin The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Escitalopram.
Progesterone Progesterone The serum concentration of Escitalopram can be increased when it is combined with Progesterone.
Apomorphine Injection Apomorphine Injection The risk or severity of serotonin syndrome can be increased when Apomorphine is combined with Escitalopram.
Infliximab Injection Infliximab Injection The metabolism of Escitalopram can be increased when combined with Infliximab.
Protriptyline Protriptyline The risk or severity of serotonin syndrome can be increased when Protriptyline is combined with Escitalopram.
Rifaximin Rifaximin The metabolism of Escitalopram can be increased when combined with Rifaximin.
Duloxetine Duloxetine The risk or severity of serotonin syndrome can be increased when Duloxetine is combined with Escitalopram.
Trospium Trospium Escitalopram may increase the central nervous system depressant (CNS depressant) activities of Trospium.
Cinacalcet Cinacalcet The metabolism of Escitalopram can be decreased when combined with Cinacalcet.
Erlotinib Erlotinib The serum concentration of Escitalopram can be increased when it is combined with Erlotinib.
Eszopiclone Eszopiclone The risk or severity of CNS depression can be increased when Escitalopram is combined with Eszopiclone.
Insulin Aspart (rDNA Origin) Injection Insulin Aspart (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Insulin aspart.
Solifenacin Solifenacin The serum concentration of Escitalopram can be increased when it is combined with Solifenacin.
Voriconazole Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Escitalopram.
Dextroamphetamine Dextroamphetamine The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Escitalopram.
Peginterferon Alfa-2b (PEG-Intron) Peginterferon Alfa-2b (PEG-Intron) The metabolism of Escitalopram can be decreased when combined with Peginterferon alfa-2b.
Pramlintide Injection Pramlintide Injection The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Escitalopram.
Sodium Oxybate Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Escitalopram.
Exenatide Injection Exenatide Injection The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Exenatide.
Ibandronate Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Escitalopram.
Isocarboxazid Isocarboxazid The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Isocarboxazid.
Ramelteon Ramelteon The risk or severity of adverse effects can be increased when Ramelteon is combined with Escitalopram.
Darifenacin Darifenacin The serum concentration of Darifenacin can be increased when it is combined with Escitalopram.
Fentanyl Fentanyl The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Fentanyl.
Pregabalin Pregabalin The therapeutic efficacy of Escitalopram can be increased when used in combination with Pregabalin.
Tipranavir Tipranavir The serum concentration of Tipranavir can be increased when it is combined with Escitalopram.
Felbamate Felbamate The risk or severity of adverse effects can be increased when Felbamate is combined with Escitalopram.
Insulin Detemir (rDNA Origin) Injection Insulin Detemir (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Insulin detemir.
Ranolazine Ranolazine The serum concentration of Escitalopram can be increased when it is combined with Ranolazine.
Abatacept Injection Abatacept Injection The metabolism of Escitalopram can be increased when combined with Abatacept.
Rasagiline Rasagiline The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Escitalopram.
Imatinib Imatinib The serum concentration of Escitalopram can be increased when it is combined with Imatinib.
Sitagliptin Sitagliptin The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Sitagliptin.
Gefitinib Gefitinib The serum concentration of Escitalopram can be increased when it is combined with Gefitinib.
Albuterol Albuterol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Escitalopram.
Paliperidone Paliperidone The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Paliperidone.
Bortezomib Bortezomib The serum concentration of Escitalopram can be increased when it is combined with Bortezomib.
Insulin Glulisine (rDNA origin) Injection Insulin Glulisine (rDNA origin) Injection The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Insulin glulisine.
Lubiprostone Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Escitalopram.
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Escitalopram.
Posaconazole Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Escitalopram.
Primaquine Primaquine The metabolism of Escitalopram can be decreased when combined with Primaquine.
Dimenhydrinate Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Escitalopram.
Lisdexamfetamine Lisdexamfetamine The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Lisdexamfetamine.
Nabilone Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Escitalopram.
Vorinostat Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Escitalopram.
Sorafenib Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Escitalopram.
Sunitinib Sunitinib The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Escitalopram.
Dronabinol Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Escitalopram.
Lapatinib Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Escitalopram.
Levocetirizine Levocetirizine The risk or severity of adverse effects can be increased when Levocetirizine is combined with Escitalopram.
Dasatinib Dasatinib The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Escitalopram.
Mexiletine Mexiletine The serum concentration of Mexiletine can be increased when it is combined with Escitalopram.
Armodafinil Armodafinil The metabolism of Escitalopram can be decreased when combined with Armodafinil.
Paclitaxel (with polyoxyethylated castor oil) Injection Paclitaxel (with polyoxyethylated castor oil) Injection The therapeutic efficacy of Castor oil can be decreased when used in combination with Escitalopram.
Temsirolimus Temsirolimus The metabolism of Escitalopram can be decreased when combined with Temsirolimus.
Nilotinib Nilotinib The metabolism of Nilotinib can be decreased when combined with Escitalopram.
Toremifene Toremifene The risk or severity of QTc prolongation can be increased when Toremifene is combined with Escitalopram.
Chloramphenicol Injection Chloramphenicol Injection The metabolism of Escitalopram can be decreased when combined with Chloramphenicol.
Desmopressin Desmopressin The risk or severity of hyponatremia can be increased when Escitalopram is combined with Desmopressin.
Betaine Betaine The therapeutic efficacy of Escitalopram can be decreased when used in combination with Glycine betaine.
OnabotulinumtoxinA Injection OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Escitalopram is combined with Botulinum toxin type A.
RimabotulinumtoxinB Injection RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Escitalopram is combined with Botulinum Toxin Type B.
Etravirine Etravirine The metabolism of Escitalopram can be decreased when combined with Etravirine.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Escitalopram.
Desvenlafaxine Desvenlafaxine The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Desvenlafaxine.
Cevimeline Cevimeline The serum concentration of Cevimeline can be increased when it is combined with Escitalopram.
Nebivolol Nebivolol The serum concentration of Nebivolol can be increased when it is combined with Escitalopram.
Flecainide Flecainide The serum concentration of Flecainide can be increased when it is combined with Escitalopram.
Certolizumab Injection Certolizumab Injection The metabolism of Escitalopram can be increased when combined with Certolizumab pegol.
Praziquantel Praziquantel The metabolism of Escitalopram can be decreased when combined with Praziquantel.
Rufinamide Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Escitalopram.
Midazolam Midazolam The risk or severity of adverse effects can be increased when Escitalopram is combined with Midazolam.
Naltrexone Injection Naltrexone Injection The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Escitalopram.
Milnacipran Milnacipran The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Milnacipran.
Dexlansoprazole Dexlansoprazole The metabolism of Escitalopram can be decreased when combined with Dexlansoprazole.
Sodium Phosphate Sodium Phosphate The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Escitalopram.
Fesoterodine Fesoterodine The serum concentration of Fesoterodine can be increased when it is combined with Escitalopram.
Degarelix Injection Degarelix Injection The risk or severity of QTc prolongation can be increased when Degarelix is combined with Escitalopram.
Betaxolol Betaxolol The serum concentration of Escitalopram can be increased when it is combined with Betaxolol.
Iloperidone Iloperidone The serum concentration of Iloperidone can be increased when it is combined with Escitalopram.
Prasugrel Prasugrel The risk or severity of bleeding can be increased when Escitalopram is combined with Prasugrel.
Lacosamide Lacosamide The risk or severity of adverse effects can be increased when Lacosamide is combined with Escitalopram.
Everolimus Everolimus The metabolism of Escitalopram can be decreased when combined with Everolimus.
Dronedarone Dronedarone Escitalopram may increase the QTc-prolonging activities of Dronedarone.
AbobotulinumtoxinA Injection AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Escitalopram is combined with Botulinum toxin type A.
Palonosetron Injection Palonosetron Injection The risk or severity of serotonin syndrome can be increased when Palonosetron is combined with Escitalopram.
Saxagliptin Saxagliptin The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Saxagliptin.
Telavancin Injection Telavancin Injection The risk or severity of QTc prolongation can be increased when Telavancin is combined with Escitalopram.
Romidepsin Injection Romidepsin Injection The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Romidepsin.
Tapentadol Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Escitalopram.
Golimumab Injection Golimumab Injection The metabolism of Escitalopram can be increased when combined with Golimumab.
Pazopanib Pazopanib The serum concentration of Escitalopram can be increased when it is combined with Pazopanib.
Asenapine Asenapine The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Asenapine.
Vigabatrin Vigabatrin The risk or severity of adverse effects can be increased when Vigabatrin is combined with Escitalopram.
Albendazole Albendazole The metabolism of Escitalopram can be decreased when combined with Albendazole.
Oxymorphone Oxymorphone The risk or severity of serotonin syndrome can be increased when Oxymorphone is combined with Escitalopram.
Dabigatran Dabigatran The risk or severity of bleeding can be increased when Escitalopram is combined with Dabigatran.
Liraglutide Injection Liraglutide Injection The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Liraglutide.
Tocilizumab Injection Tocilizumab Injection The metabolism of Escitalopram can be increased when combined with Tocilizumab.
Eribulin Injection Eribulin Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Escitalopram.
IncobotulinumtoxinA Injection IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Escitalopram is combined with Botulinum toxin type A.
Lurasidone Lurasidone The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Lurasidone.
Acetaminophen Injection Acetaminophen Injection The serum concentration of Escitalopram can be increased when it is combined with Acetaminophen.
Vilazodone Vilazodone The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Vilazodone.
Terbutaline Injection Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Escitalopram.
Linagliptin Linagliptin The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Linagliptin.
Rilpivirine Rilpivirine The metabolism of Escitalopram can be decreased when combined with Rilpivirine.
Potassium Iodide Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Escitalopram.
Cyclophosphamide Injection Cyclophosphamide Injection The metabolism of Escitalopram can be decreased when combined with Cyclophosphamide.
Abiraterone Abiraterone The metabolism of Escitalopram can be decreased when combined with Abiraterone.
Triptorelin Injection Triptorelin Injection The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Escitalopram.
Rivaroxaban Rivaroxaban The risk or severity of bleeding can be increased when Escitalopram is combined with Rivaroxaban.
Ticagrelor Ticagrelor The risk or severity of bleeding can be increased when Escitalopram is combined with Ticagrelor.
Vandetanib Vandetanib The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Vandetanib.
Clobazam Clobazam The metabolism of Escitalopram can be decreased when combined with Clobazam.
Vemurafenib Vemurafenib The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Vemurafenib.
Vismodegib Vismodegib The metabolism of Escitalopram can be decreased when combined with Vismodegib.
Axitinib Axitinib The metabolism of Axitinib can be decreased when combined with Escitalopram.
Crizotinib Crizotinib The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Escitalopram.
Cabergoline Cabergoline The risk or severity of serotonin syndrome can be increased when Cabergoline is combined with Escitalopram.
Fondaparinux Injection Fondaparinux Injection The risk or severity of bleeding can be increased when Escitalopram is combined with Fondaparinux.
Ezogabine Ezogabine The risk or severity of adverse effects can be increased when Tiagabine is combined with Escitalopram.
Iloprost Iloprost The risk or severity of bleeding can be increased when Escitalopram is combined with Iloprost.
Enzalutamide Enzalutamide The metabolism of Escitalopram can be increased when combined with Enzalutamide.
Mirabegron Mirabegron The risk or severity of urinary retention can be increased when Escitalopram is combined with Mirabegron.
Linaclotide Linaclotide The therapeutic efficacy of Linaclotide can be decreased when used in combination with Escitalopram.
Lorcaserin Lorcaserin The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Mecasermin.
Bedaquiline Bedaquiline The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Escitalopram.
Icosapent Ethyl Icosapent Ethyl The risk or severity of bleeding can be increased when Escitalopram is combined with Icosapent ethyl.
Alogliptin Alogliptin The serum concentration of Alogliptin can be increased when it is combined with Escitalopram.
Ponatinib Ponatinib The serum concentration of Ponatinib can be increased when it is combined with Escitalopram.
Pomalidomide Pomalidomide The risk or severity of adverse effects can be increased when Pomalidomide is combined with Escitalopram.
Apixaban Apixaban The risk or severity of bleeding can be increased when Escitalopram is combined with Apixaban.
Canagliflozin Canagliflozin The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Canagliflozin.
Dabrafenib Dabrafenib The serum concentration of Escitalopram can be decreased when it is combined with Dabrafenib.
Ospemifene Ospemifene The metabolism of Escitalopram can be decreased when combined with Ospemifene.
Levomilnacipran Levomilnacipran The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Levomilnacipran.
Vortioxetine Vortioxetine The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Vortioxetine.
Perampanel Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Escitalopram.
Ibrutinib Ibrutinib The serum concentration of Ibrutinib can be increased when it is combined with Escitalopram.
Ketorolac Injection Ketorolac Injection The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Ketorolac.
Simeprevir Simeprevir The serum concentration of Simeprevir can be decreased when it is combined with Escitalopram.
Dapagliflozin Dapagliflozin The serum concentration of Dapagliflozin can be increased when it is combined with Escitalopram.
Apremilast Apremilast The metabolism of Escitalopram can be increased when combined with Apremilast.
Ceritinib Ceritinib The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Escitalopram.
Siltuximab Injection Siltuximab Injection The metabolism of Escitalopram can be increased when combined with Siltuximab.
Albiglutide Injection Albiglutide Injection The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Albiglutide.
Eslicarbazepine Eslicarbazepine The risk or severity of adverse effects can be increased when Eslicarbazepine is combined with Escitalopram.
Testosterone Injection Testosterone Injection The metabolism of Escitalopram can be decreased when combined with Testosterone.
Oritavancin Injection Oritavancin Injection The metabolism of Escitalopram can be decreased when combined with Oritavancin.
Empagliflozin Empagliflozin The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Empagliflozin.
Vorapaxar Vorapaxar The risk or severity of bleeding can be increased when Escitalopram is combined with Vorapaxar.
Hydrocodone Hydrocodone Escitalopram may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Suvorexant Suvorexant Escitalopram may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Dulaglutide Injection Dulaglutide Injection The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Dulaglutide.
Edoxaban Edoxaban The risk or severity of bleeding can be increased when Escitalopram is combined with Edoxaban.
Methamphetamine Methamphetamine The risk or severity of serotonin syndrome can be increased when Metamfetamine is combined with Escitalopram.
Tasimelteon Tasimelteon The risk or severity of adverse effects can be increased when Tasimelteon is combined with Escitalopram.
Lanreotide Injection Lanreotide Injection The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Lanreotide.
Secukinumab Injection Secukinumab Injection The metabolism of Escitalopram can be increased when combined with Secukinumab.
Risperidone Injection Risperidone Injection The risk or severity of serotonin syndrome can be increased when Risperidone is combined with Escitalopram.
Insulin Human Inhalation Insulin Human Inhalation The risk or severity of hypoglycemia can be increased when Insulin human is combined with Escitalopram.
Lenvatinib Lenvatinib The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Escitalopram.
Naloxegol Naloxegol The metabolism of Escitalopram can be decreased when combined with Naloxegol.
Panobinostat Panobinostat The metabolism of Escitalopram can be decreased when combined with Panobinostat.
Haloperidol Injection Haloperidol Injection The serum concentration of Escitalopram can be increased when it is combined with Haloperidol.
Ivabradine Ivabradine The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Ivabradine.
Flibanserin Flibanserin The risk or severity of serotonin syndrome can be increased when Flibanserin is combined with Escitalopram.
Rolapitant Rolapitant The metabolism of Escitalopram can be decreased when combined with Rolapitant.
Brexpiprazole Brexpiprazole The risk or severity of serotonin syndrome can be increased when Brexpiprazole is combined with Escitalopram.
Ziprasidone Injection Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Escitalopram.
Cariprazine Cariprazine The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Cariprazine.
Eluxadoline Eluxadoline The risk or severity of constipation can be increased when Escitalopram is combined with Eluxadoline.
Insulin Degludec (rDNA Origin) Injection Insulin Degludec (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Insulin degludec.
Trabectedin Injection Trabectedin Injection The serum concentration of Trabectedin can be increased when it is combined with Escitalopram.
Rifapentine Rifapentine The metabolism of Escitalopram can be increased when combined with Rifapentine.
Defibrotide Injection Defibrotide Injection The risk or severity of bleeding can be increased when Escitalopram is combined with Defibrotide.
Brivaracetam Injection Brivaracetam Injection The risk or severity of adverse effects can be increased when Brivaracetam is combined with Escitalopram.
Cobicistat Cobicistat The metabolism of Escitalopram can be decreased when combined with Cobicistat.
Pimavanserin Pimavanserin The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Pimavanserin.
Diphenhydramine Injection Diphenhydramine Injection The risk or severity of serotonin syndrome can be increased when Diphenhydramine is combined with Escitalopram.
Rucaparib Rucaparib The serum concentration of Escitalopram can be increased when it is combined with Rucaparib.
Lixisenatide Injection Lixisenatide Injection The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Lixisenatide.
Ribociclib Ribociclib The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Ribociclib.
Parathyroid Hormone Injection Parathyroid Hormone Injection The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Escitalopram.
Doxepin (Insomnia) Doxepin (Insomnia) The risk or severity of serotonin syndrome can be increased when Doxepin is combined with Escitalopram.
Plecanatide Plecanatide The therapeutic efficacy of Plecanatide can be decreased when used in combination with Escitalopram.
Deutetrabenazine Deutetrabenazine The serum concentration of Deutetrabenazine can be increased when it is combined with Escitalopram.
Valbenazine Valbenazine The serum concentration of Valbenazine can be increased when it is combined with Escitalopram.
Safinamide Safinamide The risk or severity of serotonin syndrome can be increased when Safinamide is combined with Escitalopram.
Midostaurin Midostaurin The metabolism of Escitalopram can be decreased when combined with Midostaurin.
Abaloparatide Injection Abaloparatide Injection The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Escitalopram.
Enasidenib Enasidenib The serum concentration of Escitalopram can be increased when it is combined with Enasidenib.
Delafloxacin Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Escitalopram.
Betrixaban Betrixaban The risk or severity of bleeding can be increased when Escitalopram is combined with Betrixaban.
Letermovir Letermovir The serum concentration of Escitalopram can be increased when it is combined with Letermovir.
Semaglutide Injection Semaglutide Injection The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Semaglutide.
Tetrabenazine Tetrabenazine The serum concentration of Tetrabenazine can be increased when it is combined with Escitalopram.
Ertugliflozin Ertugliflozin The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Ertugliflozin.
Buprenorphine Injection Buprenorphine Injection Escitalopram may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Apalutamide Apalutamide The serum concentration of Escitalopram can be increased when it is combined with Apalutamide.
Lofexidine Lofexidine The therapeutic efficacy of Escitalopram can be increased when used in combination with Lofexidine.
Eliglustat Eliglustat The serum concentration of Eliglustat can be increased when it is combined with Escitalopram.
Encorafenib Encorafenib The serum concentration of Encorafenib can be increased when it is combined with Escitalopram.
Ivosidenib Ivosidenib The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Escitalopram.
Elagolix Elagolix The serum concentration of Elagolix can be increased when it is combined with Escitalopram.
Tafenoquine Tafenoquine The serum concentration of Tafenoquine can be increased when it is combined with Escitalopram.
Cannabidiol Cannabidiol The risk or severity of serotonin syndrome can be increased when Cannabidiol is combined with Escitalopram.
Dacomitinib Dacomitinib The serum concentration of Escitalopram can be increased when it is combined with Dacomitinib.
Stiripentol Stiripentol The metabolism of Escitalopram can be decreased when combined with Stiripentol.
Gilteritinib Gilteritinib The therapeutic efficacy of Escitalopram can be decreased when used in combination with Gilteritinib.
Glasdegib Glasdegib The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Glasdegib.
Lorlatinib Lorlatinib The metabolism of Lorlatinib can be decreased when combined with Escitalopram.
Rifamycin Rifamycin The metabolism of Escitalopram can be increased when combined with Rifamycin.
Prucalopride Prucalopride The therapeutic efficacy of Prucalopride can be decreased when used in combination with Escitalopram.
Magnesium Citrate Magnesium Citrate The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Escitalopram.
Emapalumab-lzsg Injection Emapalumab-lzsg Injection The metabolism of Escitalopram can be increased when combined with Emapalumab.
Caplacizumab-yhdp Injection Caplacizumab-yhdp Injection The risk or severity of bleeding can be increased when Escitalopram is combined with Caplacizumab.
Esomeprazole Injection Esomeprazole Injection The serum concentration of Escitalopram can be increased when it is combined with Esomeprazole.
Alpelisib Alpelisib The metabolism of Escitalopram can be decreased when combined with Alpelisib.
Brexanolone Injection Brexanolone Injection The risk or severity of adverse effects can be increased when Brexanolone is combined with Escitalopram.
Solriamfetol Solriamfetol The risk or severity of adverse effects can be increased when Solriamfetol is combined with Escitalopram.
Triclabendazole Triclabendazole The metabolism of Escitalopram can be decreased when combined with Triclabendazole.
Entrectinib Entrectinib The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Entrectinib.
Istradefylline Istradefylline The serum concentration of Istradefylline can be increased when it is combined with Escitalopram.
Pitolisant Pitolisant The serum concentration of Escitalopram can be decreased when it is combined with Pitolisant.
Fedratinib Fedratinib The metabolism of Fedratinib can be decreased when combined with Escitalopram.
Lefamulin Lefamulin Lefamulin may increase the QTc-prolonging activities of Escitalopram.
Phenytoin Injection Phenytoin Injection The serum concentration of Escitalopram can be increased when it is combined with Phenytoin.
Fosphenytoin Injection Fosphenytoin Injection The metabolism of Fosphenytoin can be decreased when combined with Escitalopram.
Voxelotor Voxelotor The metabolism of Voxelotor can be decreased when combined with Escitalopram.
Lumateperone Lumateperone The risk or severity of adverse effects can be increased when Lumateperone is combined with Escitalopram.
Lasmiditan Lasmiditan The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Escitalopram.
Cenobamate Cenobamate The serum concentration of Escitalopram can be decreased when it is combined with Cenobamate.
Selumetinib Selumetinib The metabolism of Selumetinib can be decreased when combined with Escitalopram.
Tucatinib Tucatinib The metabolism of Tucatinib can be decreased when combined with Escitalopram.
Lemborexant Lemborexant The risk or severity of adverse effects can be increased when Lemborexant is combined with Escitalopram.
Fenfluramine Fenfluramine The risk or severity of serotonin syndrome can be increased when Fenfluramine is combined with Escitalopram.
Fostemsavir Fostemsavir The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Escitalopram.
Octreotide Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Escitalopram.
Satralizumab-mwge Injection Satralizumab-mwge Injection The serum concentration of Escitalopram can be decreased when it is combined with Satralizumab.
Relugolix Relugolix The risk or severity of QTc prolongation can be increased when Relugolix is combined with Escitalopram.
Viloxazine Viloxazine The risk or severity of adverse effects can be increased when Escitalopram is combined with Viloxazine.
Theophylline Theophylline The serum concentration of Theophylline can be increased when it is combined with Escitalopram.
Fenoprofen Fenoprofen The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Fenoprofen.
Indomethacin Indomethacin The risk or severity of gastrointestinal bleeding can be increased when Indomethacin is combined with Escitalopram.
Mefenamic Acid Mefenamic Acid The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Mefenamic acid.
Naproxen Naproxen The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Naproxen.
Tolmetin Tolmetin The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Tolmetin.
Sulindac Sulindac The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Sulindac.
Trazodone Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Escitalopram.
Hydroxyurea Hydroxyurea The metabolism of Escitalopram can be decreased when combined with Hydroxyurea.
Phenobarbital Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with Escitalopram.
Metaxalone Metaxalone The risk or severity of serotonin syndrome can be increased when Metaxalone is combined with Escitalopram.
Levorphanol Levorphanol The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Escitalopram.
Primidone Primidone The risk or severity of adverse effects can be increased when Primidone is combined with Escitalopram.
Methsuximide Methsuximide The risk or severity of adverse effects can be increased when Methsuximide is combined with Escitalopram.
Diethylpropion Diethylpropion The risk or severity of serotonin syndrome can be increased when Diethylpropion is combined with Escitalopram.
Chlorpromazine Chlorpromazine The risk or severity of serotonin syndrome can be increased when Chlorpromazine is combined with Escitalopram.
Diazepam Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Escitalopram.
Oxazepam Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Escitalopram.
Flurazepam Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Escitalopram.
Clorazepate Clorazepate The risk or severity of adverse effects can be increased when Clorazepic acid is combined with Escitalopram.
Lorazepam Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Escitalopram.
Amantadine Amantadine The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Escitalopram.
Codeine Codeine The risk or severity of serotonin syndrome can be increased when Codeine is combined with Escitalopram.
Meprobamate Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Escitalopram.
Chlordiazepoxide Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Escitalopram.
Bromocriptine Bromocriptine The risk or severity of adverse effects can be increased when Escitalopram is combined with Bromocriptine.
Tranylcypromine Tranylcypromine The risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Escitalopram.
Phenelzine Phenelzine The risk or severity of serotonin syndrome can be increased when Phenelzine is combined with Escitalopram.
Procarbazine Procarbazine The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Escitalopram.
Ergoloid Mesylates Ergoloid Mesylates The risk or severity of serotonin syndrome can be increased when Ergoloid mesylate is combined with Escitalopram.
Minocycline Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Escitalopram.
Prochlorperazine Prochlorperazine The serum concentration of Escitalopram can be increased when it is combined with Prochlorperazine.
Thioridazine Thioridazine The risk or severity of serotonin syndrome can be increased when Thioridazine is combined with Escitalopram.
Trifluoperazine Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Escitalopram.
Sulfadiazine Sulfadiazine The risk or severity of hypoglycemia can be increased when Sulfadiazine is combined with Escitalopram.
Oxycodone Oxycodone The risk or severity of serotonin syndrome can be increased when Oxycodone is combined with Escitalopram.
Methadone Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Escitalopram.
Oxybutynin Oxybutynin The metabolism of Escitalopram can be decreased when combined with Oxybutynin.
Benztropine Benztropine The serum concentration of Escitalopram can be increased when it is combined with Benzatropine.
Maprotiline Maprotiline The risk or severity of serotonin syndrome can be increased when Maprotiline is combined with Escitalopram.
Ibuprofen Ibuprofen The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Ibuprofen.
Trihexyphenidyl Trihexyphenidyl Escitalopram may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.
Orphenadrine Orphenadrine Escitalopram may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Perphenazine Perphenazine The serum concentration of Escitalopram can be increased when it is combined with Perphenazine.
Fluphenazine Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Escitalopram.
Phentermine Phentermine The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Escitalopram.
Amoxapine Amoxapine The risk or severity of serotonin syndrome can be increased when Amoxapine is combined with Escitalopram.
Sulfasalazine Sulfasalazine The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Sulfasalazine.
Doxorubicin Doxorubicin The metabolism of Escitalopram can be decreased when combined with Doxorubicin.
Mechlorethamine Mechlorethamine The therapeutic efficacy of Escitalopram can be decreased when used in combination with Mechlorethamine.
Pyridostigmine Pyridostigmine The therapeutic efficacy of Escitalopram can be decreased when used in combination with Pyridostigmine.
Carbamazepine Carbamazepine The risk or severity of serotonin syndrome can be increased when Carbamazepine is combined with Escitalopram.
Molindone Molindone The risk or severity of adverse effects can be increased when Escitalopram is combined with Molindone.
Clonidine Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Escitalopram.
Cimetidine Cimetidine The serum concentration of Escitalopram can be increased when it is combined with Cimetidine.
Warfarin Warfarin The risk or severity of bleeding can be increased when Escitalopram is combined with Warfarin.
Clonazepam Clonazepam The risk or severity of adverse effects can be increased when Clonazepam is combined with Escitalopram.
Loperamide Loperamide The serum concentration of Escitalopram can be increased when it is combined with Loperamide.
Promethazine Promethazine The risk or severity of serotonin syndrome can be increased when Promethazine is combined with Escitalopram.
Meclofenamate Meclofenamate The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Meclofenamic acid.
Digoxin Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Escitalopram.
Loxapine Loxapine The risk or severity of serotonin syndrome can be increased when Loxapine is combined with Escitalopram.
Chloroquine Chloroquine The serum concentration of Escitalopram can be increased when it is combined with Chloroquine.
Quinine Quinine The serum concentration of Escitalopram can be increased when it is combined with Quinine.
Ethosuximide Ethosuximide The risk or severity of adverse effects can be increased when Escitalopram is combined with Ethosuximide.
Lactulose Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Escitalopram.
Sulfinpyrazone Sulfinpyrazone The risk or severity of bleeding can be increased when Escitalopram is combined with Sulfinpyrazone.
Chlorothiazide Chlorothiazide The risk or severity of hyponatremia can be increased when Escitalopram is combined with Chlorothiazide.
Chlorthalidone Chlorthalidone The risk or severity of hyponatremia can be increased when Escitalopram is combined with Chlorthalidone.
Metolazone Metolazone The risk or severity of hyponatremia can be increased when Escitalopram is combined with Metolazone.
Secobarbital Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Escitalopram.
Desipramine Desipramine The risk or severity of serotonin syndrome can be increased when Desipramine is combined with Escitalopram.
Amitriptyline Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Escitalopram.
Imipramine Imipramine The risk or severity of serotonin syndrome can be increased when Imipramine is combined with Escitalopram.
Probenecid Probenecid The metabolism of Escitalopram can be decreased when combined with Probenecid.
Quinidine Quinidine The metabolism of Escitalopram can be decreased when combined with Quinidine.
Procainamide Procainamide The serum concentration of Procainamide can be increased when it is combined with Escitalopram.
Isoniazid Isoniazid The risk or severity of serotonin syndrome can be increased when Isoniazid is combined with Escitalopram.
Rifampin Rifampin The metabolism of Escitalopram can be increased when combined with Rifampicin.
Disopyramide Disopyramide The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Escitalopram.
Valproic Acid Valproic Acid The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Escitalopram.
Tamoxifen Tamoxifen The serum concentration of Escitalopram can be increased when it is combined with Tamoxifen.
Butabarbital Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Escitalopram.
Levothyroxine Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Escitalopram.
Liothyronine Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Escitalopram.
Methimazole Methimazole The metabolism of Escitalopram can be decreased when combined with Methimazole.
Propylthiouracil Propylthiouracil The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Escitalopram.
Chlorpropamide Chlorpropamide The risk or severity of hypoglycemia can be increased when Chlorpropamide is combined with Escitalopram.
Glucagon Injection Glucagon Injection Escitalopram may increase the gastrointestinal motility reducing activities of Glucagon.
Tolbutamide Tolbutamide The risk or severity of hypoglycemia can be increased when Tolbutamide is combined with Escitalopram.
Tolazamide Tolazamide The risk or severity of hypoglycemia can be increased when Tolazamide is combined with Escitalopram.
Dextromethorphan Dextromethorphan The risk or severity of serotonin syndrome can be increased when Dextromethorphan is combined with Escitalopram.
Cyclobenzaprine Cyclobenzaprine The risk or severity of CNS depression can be increased when Escitalopram is combined with Cyclobenzaprine.
Niacin Niacin The metabolism of Escitalopram can be decreased when combined with Niacin.
Baclofen Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Escitalopram.
Doxylamine Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Escitalopram.
Cyproheptadine Cyproheptadine The therapeutic efficacy of Escitalopram can be decreased when used in combination with Cyproheptadine.
Clemastine Clemastine The risk or severity of QTc prolongation can be increased when Clemastine is combined with Escitalopram.
Chlorpheniramine Chlorpheniramine The risk or severity of serotonin syndrome can be increased when Chlorpheniramine is combined with Escitalopram.
Brompheniramine Brompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Escitalopram.
Meclizine Meclizine The serum concentration of Escitalopram can be increased when it is combined with Meclizine.
Methyclothiazide Methyclothiazide The risk or severity of hyponatremia can be increased when Escitalopram is combined with Methyclothiazide.
Hydrochlorothiazide Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Escitalopram.
Dantrolene Dantrolene The risk or severity of adverse effects can be increased when Dantrolene is combined with Escitalopram.
Chlorzoxazone Chlorzoxazone The serum concentration of Escitalopram can be increased when it is combined with Chlorzoxazone.
Carisoprodol Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Escitalopram.
Methocarbamol Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Escitalopram.
Disulfiram Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Escitalopram.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) The serum concentration of Escitalopram can be increased when it is combined with Propranolol.
Pseudoephedrine Pseudoephedrine The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Escitalopram.
Nortriptyline Nortriptyline The risk or severity of serotonin syndrome can be increased when Nortriptyline is combined with Escitalopram.
Nadolol Nadolol The serum concentration of Nadolol can be increased when it is combined with Escitalopram.
Butorphanol Injection Butorphanol Injection The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Escitalopram.
Nalbuphine Injection Nalbuphine Injection The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Escitalopram.
Oxytocin Injection Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Escitalopram.
Trimethobenzamide Trimethobenzamide The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Escitalopram.
Flavoxate Flavoxate Escitalopram may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
Papaverine Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Escitalopram.
Fluorouracil Injection Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Escitalopram.
Acetazolamide Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Escitalopram.
Calcitonin Salmon Injection Calcitonin Salmon Injection The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Escitalopram.
Ketoconazole Ketoconazole The metabolism of Escitalopram can be decreased when combined with Ketoconazole.
Pyrantel Pyrantel The risk or severity of adverse effects can be increased when Pyrantel is combined with Escitalopram.
Thiotepa Injection Thiotepa Injection The therapeutic efficacy of Escitalopram can be decreased when used in combination with Thiotepa.
Dipyridamole Dipyridamole The risk or severity of bleeding can be increased when Escitalopram is combined with Dipyridamole.
Vinblastine Vinblastine The metabolism of Escitalopram can be decreased when combined with Vinblastine.
Metoprolol Metoprolol The serum concentration of Escitalopram can be increased when it is combined with Metoprolol.
Hydroxyzine Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Escitalopram.
Thiothixene Thiothixene The risk or severity of adverse effects can be increased when Escitalopram is combined with Thiothixene.
Aspirin Aspirin The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Acetylsalicylic acid.
Salsalate Salsalate The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Salsalate.
Alprazolam Alprazolam The risk or severity of adverse effects can be increased when Escitalopram is combined with Alprazolam.
Temazepam Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Escitalopram.
Triazolam Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Escitalopram.
Dicyclomine Dicyclomine Escitalopram may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
Hyoscyamine Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Escitalopram.
Propantheline Propantheline Escitalopram may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
Diltiazem Diltiazem The serum concentration of Escitalopram can be increased when it is combined with Diltiazem.
Nifedipine Nifedipine The serum concentration of Escitalopram can be increased when it is combined with Nifedipine.
Timolol Timolol The metabolism of Timolol can be decreased when combined with Escitalopram.
Verapamil Verapamil The metabolism of Escitalopram can be decreased when combined with Verapamil.
Atenolol Atenolol The serum concentration of Atenolol can be increased when it is combined with Escitalopram.
Pindolol Pindolol The risk or severity of serotonin syndrome can be increased when Pindolol is combined with Escitalopram.
Cisplatin Injection Cisplatin Injection The therapeutic efficacy of Escitalopram can be decreased when used in combination with Cisplatin.
Diflunisal Diflunisal The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Diflunisal.
Piroxicam Piroxicam The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Piroxicam.
Glyburide Glyburide The risk or severity of hypoglycemia can be increased when Glyburide is combined with Escitalopram.
Glipizide Glipizide The risk or severity of hypoglycemia can be increased when Glipizide is combined with Escitalopram.
Indapamide Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Escitalopram.
Pentoxifylline Pentoxifylline The risk or severity of bleeding can be increased when Escitalopram is combined with Pentoxifylline.
Pentamidine Injection Pentamidine Injection The serum concentration of Escitalopram can be increased when it is combined with Pentamidine.
Labetalol Labetalol The serum concentration of Escitalopram can be increased when it is combined with Labetalol.
Leuprolide Injection Leuprolide Injection The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Escitalopram.
Gemfibrozil Gemfibrozil The metabolism of Escitalopram can be decreased when combined with Gemfibrozil.
Ketoprofen Ketoprofen The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Ketoprofen.
Pimozide Pimozide The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Pimozide.
Flurbiprofen Flurbiprofen The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Flurbiprofen.
Amiodarone Amiodarone The risk or severity of QTc prolongation can be increased when Amiodarone is combined with Escitalopram.
Buspirone Buspirone The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Buspirone.
Lovastatin Lovastatin The metabolism of Escitalopram can be decreased when combined with Lovastatin.
Ciprofloxacin Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Escitalopram.
Mesalamine Mesalamine The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Mesalazine.
Diclofenac Diclofenac The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Diclofenac.
Fluoxetine Fluoxetine The risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with Escitalopram.
Nimodipine Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Escitalopram.
Clozapine Clozapine The serum concentration of Escitalopram can be increased when it is combined with Clozapine.
Estazolam Estazolam The risk or severity of adverse effects can be increased when Escitalopram is combined with Estazolam.
Idarubicin Idarubicin The serum concentration of Idarubicin can be increased when it is combined with Escitalopram.
Ofloxacin Ofloxacin The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Escitalopram.
Clarithromycin Clarithromycin The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Escitalopram.
Etodolac Etodolac The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Etodolac.
Felodipine Felodipine The metabolism of Escitalopram can be decreased when combined with Felodipine.
Nabumetone Nabumetone The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Nabumetone.
Simvastatin Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Escitalopram.
Itraconazole Itraconazole The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Escitalopram.
Oxaprozin Oxaprozin The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Oxaprozin.
Rifabutin Rifabutin The metabolism of Escitalopram can be increased when combined with Rifabutin.
Sotalol Sotalol The serum concentration of Sotalol can be increased when it is combined with Escitalopram.
Zolpidem Zolpidem Escitalopram may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Doxazosin Doxazosin The serum concentration of Escitalopram can be increased when it is combined with Doxazosin.
Isradipine Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Escitalopram.
Omeprazole Omeprazole The serum concentration of Escitalopram can be increased when it is combined with Omeprazole.
Cisapride Cisapride The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Cisapride.
Gabapentin Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Escitalopram.
Fluvastatin Fluvastatin The serum concentration of Escitalopram can be increased when it is combined with Fluvastatin.
Venlafaxine Venlafaxine The risk or severity of serotonin syndrome can be increased when Venlafaxine is combined with Escitalopram.
Nizatidine Nizatidine The therapeutic efficacy of Escitalopram can be decreased when used in combination with Nizatidine.
Fluvoxamine Fluvoxamine The risk or severity of serotonin syndrome can be increased when Fluvoxamine is combined with Escitalopram.
Nefazodone Nefazodone The risk or severity of serotonin syndrome can be increased when Nefazodone is combined with Escitalopram.
Lamotrigine Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Escitalopram.
Losartan Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Escitalopram.
Tramadol Tramadol The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Escitalopram.
Vinorelbine Injection Vinorelbine Injection The metabolism of Escitalopram can be decreased when combined with Vinorelbine.
Moexipril Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Escitalopram.
Lansoprazole Lansoprazole The metabolism of Escitalopram can be decreased when combined with Lansoprazole.
Nicardipine Nicardipine The metabolism of Escitalopram can be decreased when combined with Nicardipine.
Bupropion Bupropion The metabolism of Escitalopram can be decreased when combined with Bupropion.
Ticlopidine Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Escitalopram.
Saquinavir Saquinavir The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Escitalopram.
Metformin Metformin The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Metformin.
Dalteparin Injection Dalteparin Injection The risk or severity of bleeding can be increased when Escitalopram is combined with Dalteparin.
Riluzole Riluzole The risk or severity of adverse effects can be increased when Riluzole is combined with Escitalopram.
Acarbose Acarbose The risk or severity of hypoglycemia can be increased when Acarbose is combined with Escitalopram.
Glimepiride Glimepiride The risk or severity of hypoglycemia can be increased when Glimepiride is combined with Escitalopram.
Ritonavir Ritonavir The serum concentration of Escitalopram can be increased when it is combined with Ritonavir.
Clomipramine Clomipramine The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Clomipramine.
Zafirlukast Zafirlukast The metabolism of Escitalopram can be decreased when combined with Zafirlukast.
Mirtazapine Mirtazapine Escitalopram may increase the serotonergic activities of Mirtazapine.
Topiramate Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Escitalopram is combined with Topiramate.
Insulin Lispro Injection Insulin Lispro Injection The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Escitalopram.
Pramipexole Pramipexole Escitalopram may increase the sedative activities of Pramipexole.
Donepezil Donepezil The therapeutic efficacy of Escitalopram can be decreased when used in combination with Donepezil.
Nelfinavir Nelfinavir The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Nelfinavir.
Azithromycin Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Escitalopram.
Loratadine Loratadine Escitalopram may increase the anticholinergic activities of Loratadine.
Carvedilol Carvedilol The serum concentration of Carvedilol can be increased when it is combined with Escitalopram.
Nilutamide Nilutamide The metabolism of Escitalopram can be decreased when combined with Nilutamide.
Selegiline Selegiline The risk or severity of serotonin syndrome can be increased when Selegiline is combined with Escitalopram.
Bicalutamide Bicalutamide The metabolism of Escitalopram can be decreased when combined with Bicalutamide.
Sertraline Sertraline The risk or severity of serotonin syndrome can be increased when Sertraline is combined with Escitalopram.
Propafenone Propafenone The serum concentration of Escitalopram can be increased when it is combined with Propafenone.
Letrozole Letrozole The metabolism of Escitalopram can be decreased when combined with Letrozole.
Tamsulosin Tamsulosin The serum concentration of Tamsulosin can be increased when it is combined with Escitalopram.
Ropinirole Ropinirole Escitalopram may increase the sedative activities of Ropinirole.
Quetiapine Quetiapine The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Quetiapine.
Cetirizine Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Escitalopram.
Paroxetine Paroxetine The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Escitalopram.
Tolcapone Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Escitalopram.
Citalopram Citalopram The risk or severity of serotonin syndrome can be increased when Citalopram is combined with Escitalopram.
Efavirenz Efavirenz The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Escitalopram.
Sildenafil Sildenafil The serum concentration of Sildenafil can be increased when it is combined with Escitalopram.
Pioglitazone Pioglitazone The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Escitalopram.
Celecoxib Celecoxib The risk or severity of bleeding can be increased when Celecoxib is combined with Escitalopram.
Rosiglitazone Rosiglitazone The metabolism of Escitalopram can be decreased when combined with Rosiglitazone.
Tolterodine Tolterodine The serum concentration of Escitalopram can be increased when it is combined with Tolterodine.
Thalidomide Thalidomide Escitalopram may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Balsalazide Balsalazide The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Balsalazide.
Nateglinide Nateglinide The serum concentration of Nateglinide can be increased when it is combined with Escitalopram.
Galantamine Galantamine The serum concentration of Escitalopram can be increased when it is combined with Galantamine.
Levetiracetam Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with Escitalopram.
Rabeprazole Rabeprazole The metabolism of Escitalopram can be decreased when combined with Rabeprazole.
Terbinafine Terbinafine The metabolism of Escitalopram can be decreased when combined with Terbinafine.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists